PBAC's latest decision on Hepatitis b surface antigen recombinant vaccine: Recommended with restriction (2018). Considered for Active immunisation against hepatitis B virus infection in adolescents and adults, listed temporarily on the NIP due to shortage of H-B-Vax II adult formulation.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Adolescents aged 10-19 years old and refugees and humanitarian entrants of all ages requiring hepatitis B vaccination.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
H-B-Vax II
Economic model
Cost-minimisation
ICER note
Cost-neutral basis; no ICER calculated as this is a temporary supply shortage response with equivalent clinical protection to comparator.